Cardiovascular DX company CardiNor AS today announces that it has signed an exclusive agreement with Demeditec for sales of the CE marked CardiNor Secretoneurin ELISA test in Germany. In addition, the agreement gives Demeditec the right to sell the test, on non-exclusive basis, in 15 countries outside Europe which includes India, South Korea, Mexico and Brazil.

The CardiNor Secretoneurin (SN) is a new biomarker test that could turn into a new gold-standard biomarker to monitor and treat millions of cardiac patients globally. SN has been shown to be a strong risk marker of mortality in several patient groups including ventricular arrhythmia, chronic heart failure and in patients with severe respiratory problems and sepsis. Thus, SN provides valuable prognostic information independent of established cardiovascular biomarkers.

Dr. Arndt Stüber, General Manager Demeditec, comments: “The field of cardiovascular diseases is becoming an important part of our core business and thus CardiNor’s Secretoneurin ELISA test is an excellent addition to our portfolio. We are convinced that our customers in the different territories will be offered an excellent diagnostic tool for research and routine”.

Dag Christiansen, CEO CardiNor, comments: “We are delighted to work with Demeditec Diagnostics, a company with extensive experience in distributing high quality laboratory research and clinical products in Germany and worldwide. Demeditec has a very strong position in the German market and the fact that they have an extensive network of partners in many countries around the world do provide CardiNor with an almost global market presence for our first-generation SN test”.

More information can be found at:
www.cardinor.com and www.demeditec.com